Y. Humblet

发表

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

E. Van Cutsem, D. V. Von Hoff, H. van de Velde, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2013, The New England journal of medicine.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Marc Peeters, Bart Neyns, E. Van Cutsem, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blunted rise in intracellular calcium in CD4 ± T cells in response to mitogen following autologous bone marrow transplantation

B. Coiffier, Y. Humblet, P. Felman, 1993, British journal of haematology.

Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer

C. Sempoux, J. Machiels, K. Haustermans, 2015, Targeted Oncology.

Phase II study of vinorelbine in patients with androgen-independent prostate cancer.

M. Piccart, D. Chopin, Y. Humblet, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data

F. Ciardiello, Y. Humblet, S. Tejpar, 2007 .

Cetuximab: an IgG1 monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours

Y. Humblet, 2004, Expert opinion on pharmacotherapy.

Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC).

J. Tabernero, Y. Humblet, D. Cunningham, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Armando Santoro, David Khayat, David Cunningham, 2004, The New England journal of medicine.

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.

J. Vandesompele, P. Laurent-Puig, E. Van Cutsem, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION WITH IRINOTECAN COMPARED WITH CURRENT CARE IN METASTATIC COLORECTAL CANCER AFTER FAILURE ON IRINOTECAN – A BELGIAN ANALYSIS

E. Van Cutsem, Y. Humblet, L. Annemans, 2007, Acta clinica Belgica.

Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?

C. Sempoux, J. Machiels, J. Canon, 2007, Liver international : official journal of the International Association for the Study of the Liver.

Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.

C. Sempoux, J. Machiels, V. Remouchamps, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.

W. Scheithauer, J. Pérez-Ruixo, Y. Humblet, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.

E. Coche, C. Sempoux, Y. Humblet, 2010, Cancer treatment reviews.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[Resistance To Chemotherapy - Recent Progress]

Y. Humblet, M. André, F. Michel, 1994 .

Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases.

C. Sempoux, J. Machiels, Y. Humblet, 2010, Surgery.

Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study

Y. Humblet, A. Zubel, A. Gramont, 2005 .

Cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study.

J. Tabernero, Y. Humblet, P. Soulié, 2005 .

An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results.

E. Van Cutsem, J. Tabernero, Y. Humblet, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Josep Tabernero, Jean-Yves Douillard, David Cunningham, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

10LBA Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial

J. Tabernero, Y. Humblet, D. Cunningham, 2009 .

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

D. Sargent, M. Ychou, R. Goldberg, 2013, The Lancet.

Regorafenib induced severe toxic hepatitis: characterization and discussion

C. Sempoux, N. Lanthier, Y. Humblet, 2016, Liver international : official journal of the International Association for the Study of the Liver.

Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab.

C. Sempoux, I. Leclercq, Y. Humblet, 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Abstract LB-174: Use of massively parallel, next-generation sequencing to identify gene mutations beyondERASthat predict response to panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC)

Y. Humblet, S. Patterson, M. Peeters, 2010 .

Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data.

E. Van Cutsem, F. Ciardiello, Y. Humblet, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer.

Y. Humblet, J. Vansteenkiste, J. Wolf, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors for long-term survival in patients with thoracic metastatic disease: a 10-year experience.

B. Weynand, P. Noirhomme, A. Poncelet, 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Monoclonal antibodies for the in vitro detection of small cell lung cancer metastases in human bone marrow.

J. Minna, A. Gazdar, Y. Humblet, 1988, European journal of cancer & clinical oncology.

Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Pooled safety data

J. Tabernero, Y. Humblet, D. Cunningham, 2008 .

Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3

N. Cascinelli, J. Naeyaert, J. Canon, 1995, International journal of cancer.

placebo- controlled, randomized phase Ib study ovarian cancer before and after chemotherapy: a multicentric Thrombopoietic effects and toxicity of interleukin-6 in patients with

M. Berlière, Y. Humblet, V. D’Hondt, 2011 .

Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study.

M. Berlière, Y. Humblet, A. V. van Oosterom, 1995, Blood.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1

P. Coulie, Y. Humblet, B. Dréno, 1999, International journal of cancer.

Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: prolonged intrathoracic tumor control and high central nervous system relapse rate. Groupe d'Oncologie-Pneumologie Clinique de l'Université Catholique de Louvain, Br

J. Canon, H. van de Velde, Y. Humblet, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

3017 POSTER Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data from the EVEREST study

F. Ciardiello, Y. Humblet, H. Gelderblom, 2007 .

Cetuximab dose-escalation in mCRC patients with no or slight skin reactions on standard treatment (EVEREST).

F. Ciardiello, Y. Humblet, M. Peeters, 2007 .

Cetuximab dose-escalation study in patients with metastatic colorectal cancer (MCRC) with no or slight skin reactions on cetuximab standard dose treatment (Everest): Preliminary PK and efficacy data of a randomized study

F. Ciardiello, Y. Humblet, H. Gelderblom, 2006 .

Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).

Y. Humblet, S. Patterson, M. Peeters, 2013 .

Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared with FOLFOX4 alone as first line treatment (tx) for metastatic colorectal cancer (mCRC): Results by Eastern Cooperative Oncology Group (ECOG) performance status (PS).

J. Tabernero, Y. Humblet, D. Cunningham, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III randomized controlled trial of panitumumab in patients with metastatic colorectal cancer: subset analyses in elderly patients and in patients with poor performance status.

B. Neyns, J. Canon, Y. Humblet, 2007 .

6095 POSTER Randomized, Open-label, Phase 3 Study of Panitumumab (Pmab) With FOLFOX4 Vs FOLFOX4 Alone as 1st-line Treatment for Metastatic Colorectal Cancer (mCRC) – the Role of Hypomagnesemia (Hypomag) on Efficacy

J. Tabernero, Y. Humblet, D. Cunningham, 2011 .

Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data)

C. Stroh, Y. Humblet, S. Tejpar, 2008 .

Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Gary Middleton, Takayuki Yoshino, Chloe E Atreya, 2018, Cancer discovery.

Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

J. Bourhis, C. Borel, Y. Humblet, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The EVEREST study: relationship between efficacy and K-RAS mutation status in patients with irinotecan-refactory MCRC treated with irinotecan and standard or escalating doses of cetuximab

C. Stroh, Y. Humblet, S. Tejpar, 2008 .

Cetuximab dose-escalation study in patients with metastatic colorectal cancer with no or slight skin reactions on cetuximab dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study.

Y. Humblet, H. Gelderblom, M. Peeters, 2007 .

An open-label, phase I study of cetuximab to assess the safety, efficacy and pharmacokinetics (PK) of different cetuximab regimens in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC).

G. Giaccone, R. Stupp, Y. Humblet, 2005 .

Quantification of CD34+ cells mobilized into the peripheral blood predicts the yield of the leukapheresis product and can replace progenitor assays.

Y. Humblet, M. André, A. Feyens, 1997, Cytokines, cellular & molecular therapy.

Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naïve patients with advanced pancreatic cancer (APC).

H. Friess, Y. Humblet, G. Bodoky, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study.

J. Canon, Y. Humblet, V. D’Hondt, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts.

J. Canon, Y. Humblet, A. Feyens, 1989, Cancer research.

Autologous peripheral blood stem cell transplantation for lung cancer.

Y. Humblet, K. Zaner, D. Rubinstein, 1999, Bailliere's best practice & research. Clinical haematology.

Immunodetection of small cell lung cancer metastases in bone marrow using three monoclonal antibodies.

Y. Humblet, H. Bazin, J. Rodhain, 1988, European journal of cancer & clinical oncology.

Clearance kinetics of CD34+ cells from peripheral blood: an independent predictor of hematologic recovery after high-dose chemotherapy and hematopoietic stem cell transplantation

J. Wuu, Y. Humblet, M. André, 1999, Bone Marrow Transplantation.

The administration of 10 microg/kg granulocyte colony-stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failed.

J. Canon, Y. Humblet, M. André, 1999, Leukemia & lymphoma.

Recombinant human interleukin-2 restores in vitro T-cell colony formation by peripheral blood mononuclear cells after autologous bone marrow transplantation.

Y. Humblet, C. Doyen, B. Châtelain, 1987, Experimental hematology.

Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)

S. Jaeger, C. Atreya, M. Ducreux, 2016 .

Correlation of high amphiregulin and epiregulin expression in KRAS wild type colorectal primaries with response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease.

I. Çelik, Y. Humblet, S. Tejpar, 2008 .

Phase II study of raltitrexed in combination with oxaliplatin as second line treatment in refractory advanced colorectal cancer

L. Dirix, C. Verslype, Y. Humblet, 2001 .

High-dose chemo-radiotherapy cycles for LD small cell lung cancer patients using G-CSF and blood stem cells.

Y. Humblet, M. Symann, P. Weynants, 1996, Bone marrow transplantation.

Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Patient-reported outcome (PRO)-assessed clinical benefit with panitumumab (Pmab) in metastatic colorectal cancer (mCRC) patients (pts)

B. Neyns, Y. Humblet, M. Peeters, 2007 .

Expression of MAGE genes in primary and metastatic cutaneous melanoma

Rika Deraemaecker, Stefan Suciu, Marie Marchand, 1995, International journal of cancer.

Diel movement of bullhead (Cottus perifretum) in a lowland stream

Marcel Eens, Alexander Kobler, M. Eens, 2012 .

Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.

Stefano Iacobelli, Francis Lévi, Antoine Adenis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Resistance to cisplatin: how to deal with the problem?

J. Canon, Y. Humblet, M. Symann, 1990, European journal of cancer.

Sequential high-dose ICE chemotherapy with circulating progenitor cells (CPC) in small cell lung cancer: an EBMT study.

M. Marangolo, L. Perey, Y. Humblet, 1996, Bone marrow transplantation.

Detection of small cell lung cancer bone marrow metastases by tumor stem cell assay.

Y. Humblet, M. Symann, 1988, Pathologie-biologie.

Chapter 22 Cytotoxicity of workshop monoclonal antibodies in the presence of complement

Y. Humblet, A. Feyens, M. Symann, 1988 .

Detection of small cell lung cancer bone marrow metastases by immunofluorescence.

J. Canon, Y. Humblet, H. Bazin, 1988, Pathologie-biologie.

Concentration of bone marrow progenitor cells by separation on a Percoll gradient using the Haemonetics model 30.

Y. Humblet, A. Feyens, M. Symann, 1988, Bone marrow transplantation.

Immunological removal of cancer cells in bone marrow autografts: setting the experimental conditions

Y. Humblet, M. Symann, A. Lebacq-Verheyden, 1984 .

Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer.

C. Penning, Y. Humblet, X. Pivot, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

PD-0034POPULATION PHARMACOKINETICS ANALYSIS OF REGORAFENIB AND ITS ACTIVE METABOLITES FROM THE PHASE III CORRECT STUDY OF METASTATIC COLORECTAL CANCER

M. Ychou, J. Tabernero, A. Grothey, 2013 .

High Amphiregulin and Epiregulin expression in K-ras wild type colorectal primaries predicts response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease

I. Çelik, Y. Humblet, S. Tejpar, 2007 .

A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium.

V. Grégoire, A. Wambersie, E. Salamon, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma.

A. Garden, K. Ang, F. Khuri, 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib

M. Ychou, R. Goldberg, H. Lenz, 2013 .

In utero exposure to chemotherapy: effect on cardiac and neurologic outcome.

L. Lagae, P. Claus, R. Paridaens, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.

C. Gisselbrecht, Y. Humblet, C. Doyen, 1992, Experimental hematology.

A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer

M. Moore, W. Vervenne, C. Verslype, 2008 .

Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study.

E. Van Cutsem, W. Vervenne, C. Verslype, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NEW DRUGS IN MEDICAL ONCOLOGY: NEW DIFFICULTIES TO DISTINGUISH DRUG-INDUCED SIDE EFFECTS FROM CANCER COMPLICATIONS: A CASE-REPORT

J. Machiels, Y. Humblet, E. Seront, 2011, Acta clinica Belgica.

Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer.

J. Machiels, M. Berlière, Y. Humblet, 2003, Gynecologic Oncology.

Time course of regorafenib-associated adverse events in the phase III CORRECT study.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab

E. Van Cutsem, Y. Humblet, G. Bodoky, 2007, British Journal of Cancer.

Vascular reconstruction during pancreatoduodenectomy for ductal adenocarcinoma of the pancreas improves respectability but does not achieve patients cure

C. Sempoux, P. Scalliet, D. Glineur, 2010 .

Period-dependent sex-biased movement in a polygamous stream fish (Cottus perifretum Freyhof, Kottelat & Nolte, 2005—Actinopterygii, Cottidae) with male parental care

M. Eens, Y. Humblet, A. Kobler, 2012, Hydrobiologia.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

E. Van Cutsem, Y. Humblet, S. Tejpar, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Ki-1 anaplastic primary cutaneous large-cell lymphoma.

Y. Humblet, A. Bourlond, C. Stenier, 1995, Dermatology.

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival

J. Machiels, J. Galon, Y. Humblet, 2018, Journal of the National Cancer Institute.

Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine.

K. Nackaerts, Y. Humblet, J. Vansteenkiste, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Evolution of Metastases in Space and Time under Immune Selection

F. Marincola, M. Ceccarelli, J. Galon, 2018, Cell.

Late Intensification Chemotherapy and Autologous Bone-marrow Transplantation in Small Cell Lung-cancer

Y. Humblet, L. Delaunois, M. Symann, 1982 .

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

D. Sargent, M. Teufel, M. Ychou, 2015, The Lancet. Oncology.

Biology of small cell lung cancer: an overview.

J. Canon, Y. Humblet, M. Symann, 1990, The European respiratory journal.

Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.

E. Van Cutsem, F. Ciardiello, Y. Humblet, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Time course of regorafenib-associated adverse events in the phase III CORRECT study

M. Ychou, R. Goldberg, H. Lenz, 2013 .

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.

S. Aamdal, J. Wanders, A. Eggermont, 2003, European journal of cancer.

Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

C. Sempoux, J. Machiels, K. Haustermans, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC)

Daniel J. Sargent, Olivier Bouché, Alberto Sobrero, 2012 .

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)

J. V. van Meerbeeck, J. Canon, Y. Humblet, 2016, PloS one.

A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data

I. Vergote, J. Canon, Y. Humblet, 2005 .

Tallimustine in advanced previously untreated colorectal cancer, a phase II study.

Y. Humblet, C. Punt, A. Polli, 1996, British Journal of Cancer.

Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients

Y. Humblet, J. Gérain, A. Ferrant, 2000, Annals of Hematology.

Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.

M. Marangolo, L. Perey, Y. Humblet, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Temperament traits and microhabitat use in bullhead, **Cottus perifretum** : fish associated with complex habitats are less aggressive

M. Eens, Y. Humblet, G. Maes, 2011 .

A phase I study of vinblastine tryptophan ester

Y. Humblet, M. Symann, A. Bosly, 2004, Cancer Chemotherapy and Pharmacology.

Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study

E. Van Cutsem, Y. Humblet, M. Debiec‐Rychter, 2008, Clinical Cancer Research.

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

E. Van Cutsem, Y. Humblet, S. Patterson, 2013, Clinical Cancer Research.

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.

P. Philip, A. Santoro, P. Karásek, 2013, European journal of cancer.

Period-dependent sex-biased movement in a polygamous stream fish (Cottus perifretum Freyhof, Kottelat & Nolte, 2005—Actinopterygii, Cottidae) with male parental care

M. Eens, Y. Humblet, A. Kobler, 2012, Hydrobiologia.

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

W. Scheithauer, E. Van Cutsem, M. Moore, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC)

Y. Humblet, M. Beauduin, M. Symann, 1990, Medical oncology and tumor pharmacotherapy.

Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study.

J. Machiels, Y. Humblet, M. Beauduin, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized study comparing 5 or 10 μg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies

J. Canon, Y. Humblet, M. André, 2003, Transfusion.

Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients.

R. Stupp, S. Peters, V. Voelter, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.

C. Sempoux, Y. Humblet, R. Lai, 2012, European journal of cancer.

Bee stings and acute tubular necrosis.

Y. Humblet, C. van Ypersele de Strihou, J. Sonnet, 1982, Nephron.

Resection of a chest chondrosarcoma invading the spine and the aorta.

Y. D'udekem, G. El khoury, Y. Humblet, 1998, The Annals of thoracic surgery.

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.

E. Van Cutsem, J. Tabernero, G. Tortora, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.

A. Bottomley, F. Lévi, Y. Humblet, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial

R. Goldberg, H. Lenz, J. Tabernero, 2016 .

Late intensification chemotherapy with autologous bone marrow infusion in small cell lung cancer: preliminary results of a randomized trial

J. Machiels, Y. Humblet, L. Delaunois, 1984 .

Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.

L. Parvinen, Y. Humblet, E. Kumpulainen, 2003, European journal of cancer.

A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.

E. Van Cutsem, L. Dirix, Y. Humblet, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Gender as a predictor for optimal dynamic scheduling of oxaliplatin, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Results from EORTC randomized phase III trial 05963

T. Gorlia, F. Lévi, J. Canon, 2005 .

Lymph node ratio and surgical quality are strong prognostic factors of rectal cancer: results from a single referral centre

C. Sempoux, P. Scalliet, Y. Humblet, 2016, Colorectal Disease.

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.

W. Scheithauer, E. Van Cutsem, B. Neyns, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Ef ﬁ cacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

J. Jassem, J. Canon, Y. Humblet, 2014 .

260 A phase II study of preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma: the RadiOxCape study

C. Sempoux, J. Machiels, P. Scalliet, 2003 .

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014 .

Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small cell lung cancer: A dose escalation study of carboplatin

D. Rodenstein, Y. Humblet, M. Beauduin, 1989, Medical oncology and tumor pharmacotherapy.

Compassionate use of Gemzar in advanced pancreatic cancer: a Belgian experience.

E. Van Cutsem, Y. Humblet, P. Gillard, 2001, Acta gastro-enterologica Belgica.

Tolerance and Effectiveness of Combined Il-3 and G-csf in Collecting Peripheral-blood Progenitor Cells (pbpc) Following Disease-oriented Chemotherapy

Y. Humblet, V. D’Hondt, C. Doyen, 1993 .

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

J. Bourhis, C. Borel, A. Schueler, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Leukocyte membrane proteins in chronic lymphocytic leukemia, as studied by two-dimensional gel electrophoresis.

K. Willard-Gallo, Y. Humblet, M. Symann, 1984, Clinical chemistry.

A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer

J. Machiels, K. Zaman, Y. Humblet, 2011, Breast Cancer Research and Treatment.

Tolerance of sequential or simultaneous administration of IL-3 and G-CSF in improving peripheral blood stem cells harvesting following multi-agent chemotherapy: a pilot study.

Y. Humblet, A. Feyens, V. D’Hondt, 1994, Bone marrow transplantation.

Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone

C. Sempoux, X. Chapaux, J. Canon, 2015, British Journal of Cancer.

Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer

Y. Humblet, M. Mano, 2008, Nature Clinical Practice Oncology.

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)

V. Torri, M. Ychou, E. Van Cutsem, 2016, ESMO Open.

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).

Scott D. Patterson, Josep Tabernero, Jean-Yves Douillard, 2013 .

Phenotypic variation of an ALK‐positive large‐cell neuroendocrine lung carcinoma with carcinoid morphology during treatment with ALK inhibitors

Y. Humblet, L. Libbrecht, D. Hoton, 2018, Histopathology.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC).

J. Tabernero, Y. Humblet, D. Cunningham, 2012, Journal of Clinical Oncology.

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

E. Van Cutsem, A. Santoro, D. Khayat, 2004, The New England journal of medicine.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitunumab (Pmab)

B. Neyns, Y. Humblet, M. Peeters, 2007 .

Evolution of Metastases in Space and Time under Immune Selection

F. Marincola, M. Ceccarelli, J. Galon, 2018, Cell.

S. Iacobelli, T. Gorlia, F. Lévi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CPT11 alternating with 5 fluorouracil (5 FU) folinic acid (FA): A multicentre phase II study in 1st line chemotherapy (CT) of metastatic colorectal cancer (CRC): Preliminary results

L. Dirix, Y. Humblet, F. Cognetti, 1997 .

180 Additional treatment does not improve the survival of locally advanced or metastatic NSCLC patients who responded after two courses of cisplatin (C), vindesin (V), mitomycin (M) chemotherapy

Y. Humblet, J. Jamart, L. Delaunois, 1997 .

DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease

P. Marynen, Y. Humblet, S. Tejpar, 2008 .